静脉对乙酰氨基酚作为老年急性重度疼痛辅助镇痛药的随机临床试验
这项随机临床试验在纽约布朗克斯两家急诊科纳入65岁及以上急性重度疼痛成人,随机接受静脉氢吗啡酮0.5 mg联合静脉对乙酰氨基酚1 g或联合100 mL生理盐水安慰剂。主要终点为60分钟时数字评定量表(NRS)疼痛评分改善的组间差异。结果显示,对乙酰氨基酚组NRS改善5.7分,安慰剂组改善5.2分,差异0.6分(95%CI -0.4 to 1.5),无临床或统计学显著差异;60分钟时要求额外镇痛的比例分别为28.7%和29.1%,差异-0.4%(95%CI -14.3% to 13.5%),亦无显著差异。两组安全性相似。
要点
- 老年急诊急性重度疼痛患者中,氢吗啡酮+静脉对乙酰氨基酚组60分钟NRS改善5.7分,氢吗啡酮+安慰剂组改善5.2分,差异0.6分(95%CI -0.4 to 1.5),无临床或统计学显著差异。
- 60分钟时要求额外镇痛者在对乙酰氨基酚组为28.7%,安慰剂组为29.1%,差异-0.4%(95%CI -14.3% to 13.5%),无统计学显著差异。
- 两组安全性特征相似。
- 每臂分配81例,对乙酰氨基酚组80例、安慰剂组79例有足够数据用于分析。
- 在急性重度疼痛老年患者治疗第一小时内,静脉对乙酰氨基酚作为氢吗啡酮辅助用药未提供优于单用氢吗啡酮的疼痛缓解。
适用人群与场景
- 年龄65岁及以上的急诊科成人患者,伴急性重度疼痛。
处置流程与药物剂量
- 随机接受静脉氢吗啡酮0.5 mg联合静脉对乙酰氨基酚1 g,或静脉氢吗啡酮0.5 mg联合100 mL生理盐水安慰剂。
研究设计与关键结果
- 随机临床试验,在纽约布朗克斯两家急诊科进行,每臂81例,对乙酰氨基酚组80例、安慰剂组79例有足够数据用于分析。
- 主要终点60分钟NRS疼痛评分改善:氢吗啡酮+静脉对乙酰氨基酚组改善5.7分,氢吗啡酮+安慰剂组改善5.2分,差异0.6分(95%CI -0.4 to 1.5),无临床或统计学显著差异。
- 60分钟时要求额外镇痛的比例:对乙酰氨基酚组28.7%,安慰剂组29.1%,差异-0.4%(95%CI -14.3% to 13.5%)。
- 两组安全性特征相似。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于65岁及以上急性重度疼痛急诊患者,在静脉氢吗啡酮0.5 mg基础上加用静脉对乙酰氨基酚1 g,在治疗第一小时内未较单用氢吗啡酮提供更优的疼痛缓解。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Older adults are at risk for undertreatment of pain. We examined intravenous (IV) acetaminophen as an analgesic adjunct to IV opioids in the care of older emergency department (ED) patients with acute severe pain.
METHODS: This was a randomized clinical trial conducted in two EDs in the Bronx, New York. Eligible adults aged 65 years and older with acute severe pain were randomized to 0.5 mg of IV hydromorphone and 1 g of IV acetaminophen or 0.5 mg of IV hydromorphone and 100 mL of normal saline placebo. The primary outcome was the between group difference in improvement of numerical rating scale (NRS) pain scores at 60 minutes. Secondary outcomes were the between-group differences in the proportion of patients who chose to forgo additional pain medications at 60 minutes; the proportion who developed side effects; the proportion who required rescue analgesia; and between-group differences in NRS pain scores at 5, 15, 30, and 45 minutes.
RESULTS: Eighty-one patients were allocated to each arm. Eighty patients in the IV acetaminophen arm and 79 patients in the placebo arm had sufficient data for analysis. At 60 minutes, patients in the hydromorphone + IV acetaminophen group improved by 5.7 NRS units while those in the hydromorphone + placebo group improved by 5.2 NRS units, for a difference of 0.6 NRS units (95% confidence interval [CI] = -0.4 to 1.5). A total of 28.7% of patients in the hydromorphone + IV acetaminophen group wanted more analgesia at 60 minutes versus 29.1% in the hydromorphone + placebo group, for a difference of -0.4% (95% CI = -14.3% to 13.5%). These differences were neither clinically nor statistically significant. Safety profiles were similar in both groups.
CONCLUSION: In this randomized clinical trial, the addition of IV acetaminophen to IV hydromorphone as an adjunctive analgesic for acute, severe, pain in older adults provided neither clinically nor statistically superior pain relief when compared to hydromorphone alone within the first hour of treatment.
参考来源
- Chang AK, Bijur PE, Ata A, et al. Randomized Clinical Trial of Intravenous Acetaminophen as an Analgesic Adjunct for Older Adults With Acute Severe Pain. Acad Emerg Med. 2018. PMID: 30118582. doi:10.1111/acem.13556
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。